12:00 AM
 | 
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MORAb-009: Phase II started

Eisai's Morphotek Inc. subsidiary began a single-arm, open-label, international Phase II trial (MORAb-009-003) to evaluate IV MORAb-009 given on days 1 and 8 of...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >